Can Amgen beat down payer resistance to Repatha with its own cost analysis?
PCSK9 heart drugs have proven to be one of the biggest commercial disappointments in recent biopharma times. Held back by payers who don’t see the value in providing the drugs even at a hefty 30% or so discount on the list price, sales of Amgen’s Repatha and Praluent from Regeneron/Sanofi have languished — further hampered by cost analysis studies that ascribe a relatively small value to the drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
